In vitro testing is adequate to support OTC availability of vaginal contraceptives -- NDMA.
This article was originally published in The Tan Sheet
VAGINAL CONTRACEPTIVE IN VITRO TESTING TO SUPPORT OTC STATUS is recommended by the Nonprescription Drug Manufacturers Association. In June 5 comments responding to the Feb. 3 vaginal contraceptive tentative final monograph ("The Tan Sheet" Feb. 6, p. 3), NDMA maintained that "in vitro and selected biologic testing should be the basis, under monograph standards, for OTC availability of vaginal spermicides."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC